B-lymphocyte antigen CD19 — Drug Target

All drugs that target B-lymphocyte antigen CD19 — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

Bispecific CD19-directed CD3-directed T Cell Engager · CD19-directed Cytolytic Antibody [EPC]

Marketed (3)

• Blincyto · Amgen · Bispecific CD19-directed CD3-directed T Cell Engager · Oncology
  Blincyto works by binding to both T cells and cancer cells, directing the T cells to kill the cancer cells.
• MONJUVI · MORPHOSYS US INC · Oncology
• Uplizna · Viela Bio · CD19-directed Cytolytic Antibody [EPC] · Neuroscience
  Uplizna works by binding to CD19 on B-lymphocytes, marking them for destruction.